Filter By Category
Archives
Share on -
ASUNERCEPT
Generic Name: ASUNERCEPT
ABSTRACT -
Asunercept is a recombinant fusion protein consisting of the extracellular domain of CD95 (Fas receptor) linked to an IgG Fc domain. It is designed to bind CD95 ligand and inhibit CD95/CD95L signaling, a pathway implicated in tumor-cell invasion, immune modulation, apoptosis, and tissue injury. It has been studied in glioblastoma, myelodysplastic syndromes, and other investigational settings.
DOSAGE -
No approved standard dosage is established. Clinical trials have used intravenous administration at protocol-defined intervals. Dose, infusion time, premedication, and monitoring depend on the study.
SIDE EFFECTS–
- Possible or reported side effects may include:
- Infusion reaction
- Fatigue
- Headache
- Nausea
- Fever or chills
- Infection risk
- Laboratory abnormalities
- Immune modulation effects
- Hypersensitivity
ALLERGIC REACTIONS -
Infusion or allergic reactions may include rash, hives, dyspnea, swelling, hypotension, fever, or anaphylaxis.
DRUG INTERACTIONS-
Use caution with:
- Chemotherapy or radiotherapy
- Other immunomodulators or biologics
- Corticosteroids or immunosuppressants
- Live vaccines
- Investigational anticancer therapies
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, and supplements they are using.
PREAUTIONS–
- Assess cancer type, prior treatment, infection status, immune status, organ function, and pregnancy status.
- Monitor during infusion and for delayed immune-related effects.
WARNINGS –
- Investigational agent; benefits and risks are not fully established.
- Serious infusion reaction, infection, or neurologic deterioration requires urgent evaluation.
- Keep out of reach of children.
- In case of overdose, severe reaction, or clinical deterioration, seek immediate medical attention.
Share on -
. Developed by